Cancer and Women’s and Men’s Health

 

 

 

Student’s Name

University

Course

Professor

Date

Cancer and Women’s and Men’s Health

Educating Patients on Risk Factors, Preventive Services, for Patients Diagnosed with Cancer, and the Potential Drug Treatments

Cancer is a formidable foe that affects both women’s and men’s health in unique ways, posing significant challenges and necessitating comprehensive approaches to prevention, detection, and treatment. Cancer is a disease that can affect both women and men. However, certain types of cancer may be more prevalent in one gender than the other (Näsman et al., 2020). For example, breast cancer is the most commonly diagnosed cancer among women worldwide, while prostate cancer is the second most commonly diagnosed cancer among men. Other more common cancer types in women include ovarian and cervical cancer, while men are more likely to develop lung and colorectal cancer (Malvezzi et al., 2018). Early detection and prevention are crucial in improving cancer treatment outcomes for both women and men. Regular cancer screenings and healthy lifestyle habits, such as maintaining a healthy weight, exercising regularly, and avoiding smoking, can significantly reduce the risk of developing cancer.

When a patient is diagnosed with cancer, it can be overwhelming and confusing. However, education and knowledge can be powerful tools in managing the disease. Healthcare professionals need to educate patients on the risk factors associated with their specific type of cancer and how they can take steps to reduce those risks (Franklin & Gkiouleka, 2021). Patients should also be informed of preventive services, such as regular cancer screenings and vaccinations. Another critical aspect of patient education is discussing the potential drug treatments for their cancer and their associated benefits and risks. This can help patients make informed decisions about their treatment plans and feel more empowered in their journey toward recovery. By providing patients with the proper education and support, they can be better equipped to manage their cancer diagnosis and improve their chances of successful treatment outcomes. The essay will focus on ovarian cancer, its pathophysiology, and the drug treatments available for patients diagnosed with this type of cancer. Additionally, the essay will explore ovarian cancer’s short-term and long-term implications.

Ovarian Cancer

Ovarian cancer is a type of cancer that starts in the ovaries, the female reproductive organs responsible for producing eggs. Ovarian cancer can develop in any part of the ovaries, including the cells that form the egg or the cells that produce hormones (Tudrej et al., 2019). This cancer can spread to other body parts, including the abdomen lining, lymph nodes, and other organs. Ovarian cancer is often called the “silent killer” because symptoms may not appear until the disease has progressed to an advanced stage (Stewart et al., 2019). Some common symptoms of ovarian cancer include bloating, pelvic pain, difficulty eating or feeling full quickly, and frequent urination. Unfortunately, these symptoms are often vague and can be attributed to other less severe conditions, which can delay diagnosis. The risk factors for ovarian cancer include age, family history, having never been pregnant, and the use of hormone replacement therapy after menopause (Symer et al., 2018). Women with a personal or family history of breast or ovarian cancer or who carry specific genetic mutations are also at higher risk of developing ovarian cancer. Diagnosis of ovarian cancer typically involves a combination of imaging tests, such as ultrasound or MRI, and blood tests to check for elevated levels of specific proteins (De La Franier & Thompson, 2019). A biopsy may be performed to confirm the diagnosis. Treatment for ovarian cancer typically involves surgery to remove as much of the cancer as possible, followed by chemotherapy to destroy any remaining cancer cells (Zhang et al., 2018). In some cases, radiation therapy may also be used. The treatment plan will depend on the stage and type of ovarian cancer and the patient’s overall health. The prognosis for ovarian cancer depends on several factors, including the cancer stage at diagnosis, the type of cancer, and the patient’s overall health. Survival rates are generally higher for women diagnosed and treated with ovarian cancer in the earlier stages. Regular check-ups and screening can help with early detection and improve outcomes for women at high risk of ovarian cancer.

The Pathophysiology of Ovarian Cancer

Ovarian cancer is a type of cancer that originates in the ovaries, which are the female reproductive organs responsible for producing and releasing eggs for fertilization. Ovarian cancer can develop in different parts of the ovary, including the epithelial cells lining the surface of the ovary, the germ cells that produce eggs, and the stromal cells that provide structural support to the ovary. The pathophysiology of ovarian cancer begins with the uncontrolled growth of abnormal cells in the ovary (Anzar et al., 2020). These cells can form a mass or tumour that can grow and spread to other body parts, including the fallopian tubes, uterus, and other nearby organs. The exact cause of ovarian cancer is not fully understood, but risk factors such as a family history of ovarian cancer, genetic mutations, age, and hormonal imbalances may increase the likelihood of developing the disease. Epithelial ovarian cancer is the most common type of ovarian cancer, accounting for about 85-90% of cases (Kim et al., 2018). This type of cancer usually develops from the cells lining the surface of the ovary, called the epithelium. Epithelial ovarian cancer can be further classified into subtypes based on the appearance of the cells under a microscope. For example, serous ovarian cancer develops from cells that produce a watery fluid, while mucinous ovarian cancer develops from cells that produce a mucus-like substance. Germ cell ovarian cancer is a less common type that develops from the cells that produce eggs (Tudrej et al., 2019). These tumours are often benign, but in some cases, they can be malignant and spread to other parts of the body. Stromal cell ovarian cancer is another rare type that develops from the cells that provide structural support to the ovary (Goyeneche et al., 2020). These types of tumours can produce hormones and cause hormonal imbalances. As ovarian cancer progresses, the tumour can invade nearby tissues and organs, such as the fallopian tubes, uterus, and bladder. Cancer can also spread to distant body parts through the lymphatic system or bloodstream, forming new tumours in other organs, such as the liver, lungs, and bones. This process is known as metastasis and is a critical factor in determining the stage and prognosis of ovarian cancer (Akhtar et al., 2019). The pathophysiology of ovarian cancer involves the uncontrolled growth of abnormal cells in the ovaries, which can form tumours and spread to other parts of the body. Different types of ovarian cancer can develop from different cell types in the ovary, and the progression of the disease is characterized by the invasion of nearby tissues and organs and the spread of cancer cells to distant sites.

The Drug Treatments used for Patients with Ovarian Cancer

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs. Several treatment options for ovarian cancer patients are available, including surgery, chemotherapy, and targeted therapy. Surgery is often the first treatment option for ovarian cancer patients (Falzone et al., 2021). Surgery aims to remove as much cancer as possible. In some cases, this may involve removing one or both ovaries and other nearby organs, such as the fallopian tubes and uterus. Surgery may also involve the removal of lymph nodes to help prevent the spread of cancer to other parts of the body. Chemotherapy is another treatment option for ovarian cancer patients (Elies et al., 2018). Chemotherapy involves the use of drugs to kill cancer cells. These drugs may be given orally or through injection into a vein. Chemotherapy is often given in cycles, with a period of treatment followed by rest. The number of cycles and the type of drugs used will depend on the stage and type of ovarian cancer. Targeted therapy is a newer type of treatment used in some cases of ovarian cancer (Lee et al., 2019). Targeted therapy drugs work by targeting specific molecules or proteins involved in the growth and spread of cancer cells. These drugs may be used alone or in combination with chemotherapy. Targeted therapy is often based on the specific characteristics of the tumour, such as the presence of specific genetic mutations. The drug treatments used for patients with ovarian cancer include surgery, chemotherapy, and targeted therapy. The treatment choice will depend on several factors, including the stage and type of ovarian cancer and the patient’s overall health and preferences. A comprehensive treatment plan may involve a combination of these therapies to achieve the best possible outcome for the patient.

The Short-Term Implications of Ovarian Cancer

Ovarian cancer is a malignant tumour that develops in the ovaries, the female reproductive organs that produce eggs. This type of cancer can have severe short-term implications for affected individuals. Some of these implications are, Firstly, symptoms of ovarian cancer may not become apparent until the cancer has advanced to later stages, making early detection difficult (Lheureux et al., 2019). This can result in delayed diagnosis, which can significantly reduce the effectiveness of treatment and increase the risk of complications. Some common symptoms of ovarian cancer include bloating, abdominal pain, frequent urination, and feeling full quickly while eating. Secondly, treatment for ovarian cancer can be invasive and aggressive, causing significant physical and emotional stress on the individual (Cartmel et al., 2021). Surgery is often necessary to remove the tumour and surrounding tissue, and chemotherapy may also be required to kill any remaining cancer cells. These treatments can cause side effects such as pain, fatigue, nausea, hair loss, and fertility problems. Thirdly, ovarian cancer can also significantly impact an individual’s daily life and well-being (Poort et al., 2021). The disease can cause physical discomfort and pain, leading to a decrease in quality of life. A cancer diagnosis can also cause emotional distress, anxiety, and depression, further affecting an individual’s mental health and overall well-being. Lastly, ovarian cancer can lead to financial strain due to the costs of medical treatment, including surgery, chemotherapy, and hospitalization (Urban et al., 2018). In addition, the individual may need to take time off work or reduce their hours, leading to a loss of income. Ovarian cancer can have severe short-term implications for affected individuals, including delayed diagnosis, invasive and aggressive treatment, decreased quality of life, and financial strain. It is essential to raise awareness about the symptoms of ovarian cancer and encourage individuals to seek medical attention promptly if they experience any of these symptoms. Early detection and treatment can improve outcomes and reduce the short-term implications of this disease.

The Long-Term Implication of Ovarian Cancer

Ovarian cancer is a severe medical condition affecting thousands of women annually. It is cancer originating in the ovaries responsible for producing eggs and female hormones. While ovarian cancer can be treated successfully in some cases, it can also have long-term implications for patients and their families. One of the primary long-term implications of ovarian cancer is its impact on a woman’s fertility (Gelderblom et al., 2022). Ovarian cancer treatment often involves surgery to remove one or both ovaries, making it difficult or impossible for women to conceive. Even if the ovaries are not removed, radiation and chemotherapy treatments can damage a woman’s reproductive system. This can be devastating for women who hope to have children in the future. Another long-term implication of ovarian cancer is the risk of recurrence (Hoppenot et al., 2018). While many women with ovarian cancer respond well to treatment and go into remission, cancer can come back months or even years later. In some cases, cancer may be more aggressive and resistant to treatment the second time, making it even more challenging to manage. Ovarian cancer can also have psychological and emotional implications long after treatment (Bober et al., 2018). Women diagnosed with ovarian cancer may experience anxiety, depression, and fear of recurrence. They may also have to deal with physical changes caused by surgery, such as removing one or both ovaries or a hysterectomy. Finally, the long-term financial implications of ovarian cancer can be significant. Treatment for ovarian cancer can be expensive, and many women may struggle to cover the cost of medical bills and other expenses (Tanay & Armes, 2019). Women unable to work during treatment may also experience a loss of income, which can have long-term financial consequences for themselves and their families. Ovarian cancer can have long-term implications for women and their families. From the impact on fertility to the risk of recurrence, the psychological and emotional toll, and the financial burden, the effects of ovarian cancer can last long after treatment has ended. It is crucial for women who have been diagnosed with ovarian cancer to seek support and care from their healthcare providers, as well as from friends and family, to help them manage these long-term implications.

Conclusion

In conclusion, ovarian cancer is a complex disease that significantly threatens women’s health. Understanding the pathophysiology of ovarian cancer is essential in developing effective drug treatments for patients. In addition to drug treatments, educating patients on the risk factors and preventive services is crucial in the early detection and prevention of ovarian cancer. Healthcare providers must take a comprehensive approach when treating ovarian cancer, considering the short-term implications and the long-term effects on patients’ physical and emotional well-being. With ongoing research and patient education, we can continue to make strides in the fight against ovarian cancer and improve the quality of life for those diagnosed with this disease.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

References

Akhtar, M., Haider, A., Rashid, S., & Al-Nabet, A. D. M. (2019). Paget’s “seed and soil” theory of cancer metastasis: an idea whose time has come. Advances in anatomic pathology, 26(1), 69-74. https://doi.org/10.1097/PAP.0000000000000219

Anzar, N., Hasan, M. R., Akram, M., Yadav, N., & Narang, J. (2020). Systematic and validated techniques for the detection of ovarian cancer emphasizing the electro-analytical approach. Process biochemistry, 94, 126-135. https://doi.org/10.1016/j.procbio.2020.04.006

Bober, S. L., Recklitis, C. J., Michaud, A. L., & Wright, A. A. (2018). Improvement in sexual function after ovarian cancer: effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer, 124(1), 176-182. https://doi.org/10.1002/cncr.30976

Cartmel, B., Hughes, M., Ercolano, E. A., Gottlieb, L., Li, F., Zhou, Y., … & Irwin, M. L. (2021). Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women’s Activity and Lifestyle Study in Connecticut (WALC). Gynecologic oncology, 161(2), 587-594. https://doi.org/10.1016/j.ygyno.2021.02.036

De La Franier, B., & Thompson, M. (2019). Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology. Biosensors and Bioelectronics, 135, 71-81. https://doi.org/10.1016/j.bios.2019.03.041

Elies, A., Rivière, S., Pouget, N., Becette, V., Dubot, C., Donnadieu, A., … & Bonneau, C. (2018). The role of neoadjuvant chemotherapy in ovarian cancer. Expert Review of Anticancer Therapy, 18(6), 555-566. https://doi.org/10.1080/14737140.2018.1458614

Falzone, L., Scandurra, G., Lombardo, V., Gattuso, G., Lavoro, A., Distefano, A. B., … & Scollo, P. (2021). A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer. International Journal of Oncology, 59(1), 1-14. https://doi.org/10.3892/ijo.2021.5233

Franklin, P., & Gkiouleka, A. (2021). A scoping review of psychosocial risks to health workers during the Covid-19 pandemic. International Journal of Environmental Research and Public Health, 18(5), 2453. https://doi.org/10.3390/ijerph18052453

Gelderblom, M. E., IntHout, J., Hermens, R. P., Coppus, S. F., Ebisch, I., van Ginkel, A. A., … & Piek, J. M. (2022). STop OVarian CAncer (STOPOVCA) young: Protocol for a multicenter follow-up study to determine the long-term effects of opportunistic salpingectomy on age at menopause. Maturitas, 159, 62-68. https://doi.org/10.1016/j.maturitas.2022.01.006

Goyeneche, A., Lisio, M. A., Fu, L., Srinivasan, R., Valdez Capuccino, J., Gao, Z. H., & Telleria, C. (2020). The capacity of high-grade serous ovarian cancer cells to form multicellular structures spontaneously along disease progression correlates with their orthotopic tumorigenicity in immunosuppressed mice. Cancers, 12(3), 699. https://doi.org/10.3390/cancers12030699

Hoppenot, C., Eckert, M. A., Tienda, S. M., & Lengyel, E. (2018). Who are the long-term survivors of high grade serous ovarian cancer?. Gynecologic oncology, 148(1), 204-212. https://doi.org/10.1016/j.ygyno.2017.10.032

Kim, J., Park, E. Y., Kim, O., Schilder, J. M., Coffey, D. M., Cho, C. H., & Bast Jr, R. C. (2018). Cell origins of high-grade serous ovarian cancer. Cancers, 10(11), 433. https://doi.org/10.3390/cancers10110433

Lee, J. M., Minasian, L., & Kohn, E. C. (2019). New strategies in ovarian cancer treatment. Cancer, 125, 4623-4629. https://doi.org/10.1002/cncr.32544

Lheureux, S., Braunstein, M., & Oza, A. M. (2019). Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: a cancer journal for clinicians, 69(4), 280-304. https://doi.org/10.3322/caac.21559

Malvezzi, M., Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., La Vecchia, C., & Negri, E. (2018). European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Annals of Oncology, 29(4), 1016-1022. https://doi.org/10.1093/annonc/mdy033

Näsman, A., Du, J., & Dalianis, T. (2020). A global epidemic increase of an HPV‐induced tonsil and tongue base cancer–potential benefit from a pan‐gender use of HPV vaccine. Journal of internal medicine, 287(2), 134-152. https://doi.org/10.1111/joim.13010

Poort, H., Fenton, A. T., Thompson, E., Dinardo, M. M., Liu, J. F., Arch, J. J., & Wright, A. A. (2021). Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecologic Oncology, 160(1), 227-233. https://doi.org/10.1016/j.ygyno.2020.10.034

Stewart, C., Ralyea, C., & Lockwood, S. (2019). Ovarian cancer: an integrated review. In Seminars in oncology nursing (Vol. 35, No. 2, pp. 151-156). WB Saunders. https://doi.org/10.1016/j.soncn.2019.02.001

Symer, M. M., Wong, N. Z., Abelson, J. S., Milsom, J. W., & Yeo, H. L. (2018). Hormone replacement therapy and colorectal cancer incidence and mortality in the prostate, lung, colorectal, and ovarian cancer screening trial. Clinical colorectal cancer, 17(2), e281-e288. https://doi.org/10.1016/j.clcc.2018.01.003

Tanay, M. A., & Armes, J. O. (2019). Lived experiences and support needs of women who developed chemotherapy‐induced peripheral neuropathy following treatment for breast and ovarian cancer. European Journal of Cancer Care, 28(3), e13011. https://doi.org/10.1111/ecc.13011

Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019). Characteristics of in vivo model systems for ovarian cancer studies. Diagnostics, 9(3), 120. https://doi.org/10.3390/diagnostics9030120

Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019). Characteristics of in vivo model systems for ovarian cancer studies. Diagnostics, 9(3), 120. https://doi.org/10.3390/diagnostics9030120

Urban, R. R., He, H., Alfonso, R., Hardesty, M. M., & Goff, B. A. (2018). The end of life costs for Medicare patients with advanced ovarian cancer. Gynecologic oncology, 148(2), 336-341. https://doi.org/10.1016/j.ygyno.2017.11.022

Zhang, Y., Liu, Z., Thackray, B. D., Bao, Z., Yin, X., Shi, F., … & Di, W. (2018). Intraoperative Raman‐guided chemo‐photothermal synergistic therapy of advanced disseminated ovarian cancers. Small, 14(31), 1801022. https://doi.org/10.1002/smll.201801022

If you are having challenges with writing your nursing essay either because of lack of time or not knowing where to start, you can order your paper here